Wells Fargo & Company Gemini Therapeutics, Inc. Put Options Transaction History

Wells Fargo & Company

  • $434 Billion
  • Q3 2024

Put Options

0 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
No transaction found.

Others Institutions Holding GMTX

# of Institutions
1
Shares Held
2.44M
Call Options Held
0
Put Options Held
0
View Full List

About Gemini Therapeutics, Inc.

GMTX Quotes by TradingView
  • Ticker GMTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,244,500
  • Market Cap $1.05B
  • Description
  • Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...
More about GMTX
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email